Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Global Coalition Urges Regulatory Convergence On COVID-19 Vaccines

More Funding Still Needed For COVAX Initiative

Executive Summary

Mutual recognition of approvals and simplified rules on labeling could help to make COVID-19 vaccines more accessible to populations around the world. 

You may also be interested in...



Coronavirus Notebook: Moderna Renounces COVID-19 Patents, China Joins COVAX

The CEPI coalition plans a global network to assess and compare the immunological responses generated by COVID-19 vaccine candidates, and a trial gets under way to test whether the BCG vaccine can afford some immunity against coronavirus.

Coronavirus Notebook: COVAX Wellcomes Latecomers, Sanofi/GSK Sign Canadian Supply Deal

The Australian government is investing in two candidate vaccines being developed in Melbourne, French firm Avaxia is looking at the virucidal potential of an antibacterial compound, and Canada has ordered millions of specialist vials and syringes from an advanced materials science firm based in Alabama.

Russia’s Sputnik V COVID-19 Vaccine Starts EU Rolling Review

The Russian backers of the vaccine’s development say that if it receives a marketing authorization in the EU, distribution could begin in June this year.

Topics

Related Companies

UsernamePublicRestriction

Register

OM007466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel